title: Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
abstract: OBJECTIVE
  Gaucher disease in India has been reported only in a few case reports from India. The aim of the study was to assess the response to enzyme replacement therapy in Indian patients with Gaucher disease.
  
  
  METHODS
  Retrospective analysis of patients receiving CHO-derived recombinant macrophage-targetted glucocorebrosidase.
  
  
  METHODS
  Five centers from India with experience in treating lysosomal storage disorders.
  
  
  METHODS
  The diagnosis of Gaucher disease was confirmed by low glucocerebrosidase levels, though it was first made on splenectomy in 8 and on bone marrow examination in 9 patients. Twenty five of 52 patients diagnosed with Gaucher disease (17 Type I, 8 mild Type III) received treatment for >6 months. Indications for treatment included symptomatic anemia, thrombo-cytopenia, organomegaly, bone disease or mild neurological symptoms leading to impairment of quality of life. Patients with significant neurological involvement were excluded. The drug infusions were given intravenously every 15 days.
  
  
  METHODS
  Hemoglobin, platelet counts, liver and spleen volumes and growth parameters.
  
  
  RESULTS
  22 of the 25 children who survived were analyzed. After 6 months of treatment, the mean (range) increase in hemoglobin was 1.5 (-3.4 to 6.1) g/dL (P=0.01) and in platelet count was 32 x 10(9)/L (-98.5 x 109 to 145.5 x10(9))/L (P=0.02). The mean (range) increase in weight was 3 kg (-5.6 to 10.5) (P=0.04) and in height was 7.1 cm (0 to 26.5) (P=0.0003). Liver size decreased by a mean (range) of 38.5% (- 5.5 to 86.7) (P=0.0003) and the spleen size by 34.8% (0 to 91.7) (P=0.004). All patients had improvement in bone pains and in 2 patients, neurological symptoms improved with others remaining static.
  
  
  CONCLUSIONS
  This is the first reported cohort of patients in India reporting our experience with imiglucerase enzyme replacement therapy for treatment of Gaucher Disease in India.
authors.affiliation: Department of Gastroenterology, Jaslok Hospital and Research Centre, Mumbai, India. aabhanagral@gmail.com
authors.forename: A
authors.initials: A
authors.lastname: Nagral
authors.forename: P
authors.initials: P
authors.lastname: Mewawalla
authors.forename: S
authors.initials: S
authors.lastname: Jagadeesh
authors.forename: M
authors.initials: M
authors.lastname: Kabra
authors.forename: S R
authors.initials: SR
authors.lastname: Phadke
authors.forename: I C
authors.initials: IC
authors.lastname: Verma
authors.forename: R D
authors.initials: RD
authors.lastname: Puri
authors.forename: N
authors.initials: N
authors.lastname: Gupta
authors.forename: P S
authors.initials: PS
authors.lastname: Kishnani
authors.forename: P K
authors.initials: PK
authors.lastname: Mistry
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D056947:Enzyme Replacement Therapy / Q000379:methods*; D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy* / Q000201:enzymology; D005962:Glucosylceramidase / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007194:India; D007223:Infant; D008264:Macrophages / Q000187:drug effects / Q000201:enzymology; D008297:Male; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D005962:Glucosylceramidase; C090568:imiglucerase